Anixa Biosciences Inc logo

Anixa Biosciences Inc

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. Anixa's proprietary Somatichrome™ technology platform allows for the targeting of any antigen to the cell surface for presentation via a novel endogenous immune receptor known as the i-CAR (Immune Cell-Associated Recognition). This vector reutilization approach is designed to enable a best-in-class antibody replacement strategy. Anixa has established a diverse pipeline of product candidates in inactivated virus, toxoid and tumor antigens that includes several Phase II cancer vaccine candidate assets. Anixa's lead cancer vaccine asset is VGX-3100, the first antigen-specific cancer vaccine candidate focused on Merkel cell carcinoma.

Latest events on Quartr

Previous Events for Anixa Biosciences Inc




United States of America

About the company

Investor Relations page

Dig deeper into the fundamentals using Quartr - Investor relations

  • Skip straight to the Q&A session
  • Receive notifications about new events
  • Connect the financial calender on your phone
  • Figure out why the stock is up or down
  • Read the transcripts or scroll the deck
  • Access earnings or press releases
Android play link
App store link
Quartr app screenshot